

# AQUARRAY STARTED NUMEROUS COOPERATIONS



**AQUARRAY HAS FIRST RESULTS TO SHOW WITHIN NUMEROUS PARTNERSHIPS WITH EQUIPMENT AND BIOTECHNOLOGY COMPANIES TO SOLVE SCREENING PROBLEMS.**

Aquarray's DMA technology enables miniaturisation of screening experiments, resulting in significant material and cost savings. Recognizing the potential, numerous equipment and biotechnology companies have partnered with Aquarray to solve specific analytical problems.

One important topic is increasing the efficiency of cell screening with standard dispensers as well as with normal and special cell media. Other topics relate to MALDI-MS analysis, such as high-throughput readout of high-density droplet microarrays based on MALDI-MS, to enable the next generation of on-chip drug discovery, or modified target surfaces to improve performance in MALDI-MS analysis. Relevant application notes can be found on the Aquarray website <https://www.aquarray.com/application-notes>.

To support Aquarray's continued development and growth, Dr. Tim Friedrichson has been appointed CEO of the company. He previously worked in the start-up industry and as a translation manager at the Max Planck Institute of Molecular Cell Biology and Genetics. The previous CEO, Dr. Angelika Weinländer, has left the company.

## **ABOUT AQUARRAY**

Aquarray is a spin-off of the Karlsruhe Institute of Technology (KIT), founded in April 2018, based on the scientific work of Prof. Dr. Pavel Levkin and with the support of the EXIST Research Funding programme of the Federal Ministry for Economic Affairs and Climate Action, the ERC Proof-of-Concept Grant of the European Union and the European Union's Horizon 2020 research and innovation programme under grant agreement no. 880019.

**Contact for more information:** Dr. Tim Friedrichson ([tim.friedrichson@aquarray.com](mailto:tim.friedrichson@aquarray.com))